Company attributes
Other attributes
EntheogeniX Biosciences is a biopharmaceutical company using artificial intelligence and computational biophysics to discovery new medicines based on psychedelics that is headquartered in Wilmington, Delaware and was founded in 2019 as a joint venture between ATAI Life Sciences AG and Cyclica Inc. EntheogeniX Biosciences is focused on discovering and developing psychedelic research for the creation of more effective treatments for mental health conditions such as depression, bipolar disorder, and schizophrenia.
The joint venture of EntheogeniX Biosciences was announced on November 11, 2019 with the goal of streamlining the drug discovery process for developing treatments for mental health disorders. The president and CEO of Cyclica, Naheed Kurji, made the following statement about his company's decision to team up with ATAI Life Sciences to create EntheogeniX Biosciences:
Our vision is to spark a new era of drug discovery centred on a robust computation-centric approach. We are especially passionate about advancing health outcomes for patients suffering with the most complex and prevalent disorders like depression, which is the leading cause of disability worldwide. We’re thrilled to partner with the world-class team at ATAI on this paradigm shifting venture.
